Observational studyJournal of neurology2026
Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnti-CD20 monoclonal antibodies, such as ofatumumab, have significantly improved the management of multiple sclerosis (MS). Still, their long-term immunological effects, particularly on non-B-cell populations, remain poorly explored. We characterized longitudinal changes in circulating lymphocyte subsets and explored their clinical correlates in people with MS treated with ofatumumab.
methodsWe conducted an observational cohort study including adults with MS who initiated ofatumumab and had paired baseline and on‑treatment assessments after at least 2 years (n=34). Immunophenotyping quantified total lymphocytes and subsets (CD3+, CD3+CD4+, CD3+CD8+, CD19+, CD20+, CD56+, CD27+, CD27+CD3+, CD27+CD19+, CD3+CD20 +). Longitudinal change was modeled with linear mixed‑effects regression (fixed effects: age, sex, follow‑up duration, comorbidities, BMI, previous DMT; random intercept for subject). Annualized percentage change of each laboratory measure was related to relapses, MRI activity, EDSS progression, NEDA‑3, and EDSS improvement using multivariable logistic regression with the same covariates.
resultsOver approximately 2 years of treatment, we observed increased total lymphocytes (Coeff 251.47; 95% CI 29.29-473.64; p=0.027), CD3+ (368.79; 183.66-553.91; p<0.01), CD3+CD4+ (239.82; 107.32-372.33; p<0.01), CD3+CD8+ (132.36; 52.92-211.80; p<0.01), CD27+ (275.37; 124.11-426.63; p<0.01), and CD27+CD3+ lymphocytes (451.99; 300.40-603.58; p<0.01), and decreased CD19+ (- 181.55; -234.40 to -128.70; p<0.01), CD20+ (- 181.55; -234.40 to -128.70; p<0.01), and CD27+CD19+ lymphocytes (- 1.82; -2.74 to -0.91; p<0.01). No significant associations emerged between changes of lymphocytes and relapses, MRI activity, EDSS progression, NEDA‑3, or EDSS improvement.
conclusionIn this exploratory, descriptive, real-world cohort, ofatumumab was associated with sustained B-cell depletion (CD19+/CD20 +) and parallel increases in broad T-cell compartments. No associations with clinical or MRI outcomes were detected; these negative findings should be interpreted cautiously within the hypothesis-generating design, given the small sample size and low frequency of disease-activity events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.